The linked FDA records identify Ortho Clinical Diagnostics Inc. (QuidelOrtho) as applicant on two 510(k) submissions received 30 December 2025 and decided 4 September 2026, both with decision code SESE, meaning Substantially Equivalent. The filings list a San Diego, California address at 9975 Summers Ridge Rd., the same address QuidelOrtho Corporation publishes on its product pages. The applicant name on the two filings differs slightly in punctuation, appearing as Ortho Clinical Diagnostics Inc. (QuidelOrtho) on one and Ortho-Clinical Diagnostics, Inc. (QuidelOrtho) on the other. [1][2][5]
The two cleared submissions
K254262 covers Sofia Influenza A+B FIA, Sofia RSV FIA and Sofia Strep A+ FIA, with product code PSZ and regulation number 866.3328, in the device category for devices detecting influenza A, B and C virus antigens. K254264 covers Sofia 2 SARS Antigen+ FIA and Sofia 2 Lyme FIA, with product code QVF and regulation number 866.3982, in the category for simple point-of-care devices detecting SARS-CoV-2 viral targets from clinical specimens in near-patient settings. Both records list the advisory committee as Microbiology, clearance type as Dual Track, third-party review as No, and a summary as available. [1][2]
The FDA 510(k) database page for K254264 links a Summary and a Decision Summary, states that the submission was not reviewed by a third party, is not a combination product, and has no authorized predetermined change control plan. The page carries a last-updated date of 26 October 2026. [4]
What the Sofia assays are documented to detect
QuidelOrtho describes Sofia Influenza A+B FIA as a fluorescent immunoassay using immunofluorescence-based lateral-flow technology to detect influenza A and influenza B viral nucleoprotein antigens, for use with Sofia 2 and Sofia analyzers. The company states that Sofia 2 with Advance Result Technology delivers automated results in as few as three minutes. Catalog numbers listed are 20218 for the US and 20254 for XUS, each a test kit with a 25/12 kit and case size. [5][8]
Sofia RSV FIA is described as detecting RSV nucleoprotein antigen directly from nasopharyngeal swab and nasopharyngeal aspirate/wash specimens from symptomatic patients, for use with Sofia 2 and Sofia analyzers, with catalog number 20260 for the US. Sofia Strep A+ FIA is described as detecting Group A Streptococcal antigens from throat swabs of symptomatic patients, for use with Sofia 2 and Sofia analyzers. [6][10]
The Sofia platform page describes the platform as combining lateral-flow technology with fluorescence chemistry and assay development, and lists it alongside the Savanna, Solana and Thyretain product lines. QuidelOrtho states that product availability varies by country and is subject to local regulatory requirements. [7]
Applicant, brand and documentation
The filings name the applicant as Ortho Clinical Diagnostics Inc. (QuidelOrtho), while the product pages are published under QuidelOrtho Corporation, which lists 9975 Summers Ridge Road, San Diego, CA 92121 as its address. The public documents do not document the corporate relationship between the applicant entity and QuidelOrtho Corporation beyond the shared name in parentheses and the shared address. [1][2][5]
A technical document search filtered to catalog numbers 20218 and 20254 returns 61 results, including a CLSI document for Sofia Influenza A+B FIA dated 2017-07-01 and an FAQ document, sorted across categories such as reagent instructions for use and package inserts. A CLIA search for document number K254262 returns three results. [9][3]
Scope of the supplied collection
The supplied portfolio snapshot, retrieved 20 November 2026, links two records, both 510(k) submissions, and both with decision code SESE. The record sample contains the same two entries, so the sample decision counts and the collection decision counts both show two SESE decisions. These counts describe the supplied filings only and are not measures of total company sales, total portfolio or safety performance. No recall records are included in the snapshot. [1][2]


